PREVENTION OF THROMBOTHIC COMPLICATIONS IN CANCER PATIENTS IN HIGH-RISK GROUPS

PREVENTION OF THROMBOTHIC COMPLICATIONS IN CANCER PATIENTS IN HIGH-RISK GROUPS

Venous thromboembolism (VTE) is a common complication in patients with malignant disease. Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. Several risk factors for developing venous thrombosis usually coexist in cancer patients including surgery, hosp...

Full description

Bibliographic Details
Main Author: V. V. PTUSHKIN
Format: Article
Language:Russian
Published: Remedium Group LLC 2017-06-01
Series:Медицинский совет
Subjects:
oncology
thrombosis
prophylaxis
low molecular weight heparins
bemiparin
Online Access:https://www.med-sovet.pro/jour/article/view/1891
id doaj-8b93c714fac34546a4088d8a580d012f
record_format Article
spelling doaj-8b93c714fac34546a4088d8a580d012f2021-07-28T13:29:29ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902017-06-0106889210.21518/2079-701X-2017-6-88-921868PREVENTION OF THROMBOTHIC COMPLICATIONS IN CANCER PATIENTS IN HIGH-RISK GROUPSV. V. PTUSHKIN0ГКБ им. С.П. Боткина ДЗ г. МосквыVenous thromboembolism (VTE) is a common complication in patients with malignant disease. Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. Several risk factors for developing venous thrombosis usually coexist in cancer patients including surgery, hospital admissions and immobilization, the presence of an indwelling central catheter, chemotherapy. Effective prophylaxis and treatment of VTE reduced morbidity and mortality, and improved quality of life. Low-molecular-weight heparin (LMWH) is preferred as an effective and safe means for prophylaxis and treatment of VTE.https://www.med-sovet.pro/jour/article/view/1891oncologythrombosisprophylaxislow molecular weight heparinsbemiparin
collection DOAJ
language Russian
format Article
sources DOAJ
author V. V. PTUSHKIN
spellingShingle V. V. PTUSHKIN
PREVENTION OF THROMBOTHIC COMPLICATIONS IN CANCER PATIENTS IN HIGH-RISK GROUPS
Медицинский совет
oncology
thrombosis
prophylaxis
low molecular weight heparins
bemiparin
author_facet V. V. PTUSHKIN
author_sort V. V. PTUSHKIN
title PREVENTION OF THROMBOTHIC COMPLICATIONS IN CANCER PATIENTS IN HIGH-RISK GROUPS
title_short PREVENTION OF THROMBOTHIC COMPLICATIONS IN CANCER PATIENTS IN HIGH-RISK GROUPS
title_full PREVENTION OF THROMBOTHIC COMPLICATIONS IN CANCER PATIENTS IN HIGH-RISK GROUPS
title_fullStr PREVENTION OF THROMBOTHIC COMPLICATIONS IN CANCER PATIENTS IN HIGH-RISK GROUPS
title_full_unstemmed PREVENTION OF THROMBOTHIC COMPLICATIONS IN CANCER PATIENTS IN HIGH-RISK GROUPS
title_sort prevention of thrombothic complications in cancer patients in high-risk groups
publisher Remedium Group LLC
series Медицинский совет
issn 2079-701X
2658-5790
publishDate 2017-06-01
description Venous thromboembolism (VTE) is a common complication in patients with malignant disease. Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. Several risk factors for developing venous thrombosis usually coexist in cancer patients including surgery, hospital admissions and immobilization, the presence of an indwelling central catheter, chemotherapy. Effective prophylaxis and treatment of VTE reduced morbidity and mortality, and improved quality of life. Low-molecular-weight heparin (LMWH) is preferred as an effective and safe means for prophylaxis and treatment of VTE.
topic oncology
thrombosis
prophylaxis
low molecular weight heparins
bemiparin
url https://www.med-sovet.pro/jour/article/view/1891
work_keys_str_mv AT vvptushkin preventionofthrombothiccomplicationsincancerpatientsinhighriskgroups
_version_ 1721274167740858368

Similar Items